BCAX vs IMVT vs RCUS vs KYMR vs BMY

For growth investors, Bristol-Myers Squibb Company (BMY) is the stronger pick with -0.

2% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). Bristol-Myers Squibb Company (BMY) offers the better valuation at 16. 3x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate Bicara Therapeutics Inc. Common Stock (BCAX) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Kymera Therapeutics, Inc.

(KYMR) delivered a total return of +92. 1%, compared to -18. 6% for Arcus Biosciences, Inc. (RCUS). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus BCAX's -1. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bristol-Myers Squibb Company (BMY) is the lower-risk stock at 0.

50β versus Arcus Biosciences, Inc. 's 1. 95β — meaning RCUS is approximately 288% more volatile than BMY relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 3% for Bristol-Myers Squibb Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Bristol-Myers Squibb Company (BMY) is pulling ahead at -0.

2% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: Bristol-Myers Squibb Company grew EPS 178. 2% year-over-year, compared to -45. 2% for Immunovant, Inc.. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bristol-Myers Squibb Company (BMY) is the more profitable company, earning 14.

6% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 14. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BMY leads at 26. 3% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for IMVT: 67.

2% to $45. 50.

In this comparison, BMY (4.

4% yield) pays a dividend. BCAX, IMVT, RCUS, KYMR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Bristol-Myers Squibb Company (BMY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

50), 4. 4% yield). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BMY: +6. 7%, RCUS: +45. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BCAX is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; RCUS is a small-cap quality compounder stock; KYMR is a small-cap quality compounder stock; BMY is a mid-cap deep-value stock. BMY pays a dividend while BCAX, IMVT, RCUS, KYMR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.